Simbrunner, Benedikt http://orcid.org/0000-0001-8181-9146
Villesen, Ida Falk
Scheiner, Bernhard
Paternostro, Rafael
Schwabl, Philipp
Stättermayer, Albert Friedrich
Marculescu, Rodrig
Pinter, Matthias
Quehenberger, Peter
Trauner, Michael
Karsdal, Morten
Lisman, Ton
Reiberger, Thomas
Leeming, Diana Julie
Mandorfer, Mattias http://orcid.org/0000-0003-2330-0017
Clinical trials referenced in this document:
Documents that mention this clinical trial
Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis
https://doi.org/10.1007/s12072-020-10112-3
Bacterial translocation occurs early in cirrhosis and triggers a selective inflammatory response
https://doi.org/10.1007/s12072-023-10496-y
FXR-FGF19 signaling in the gut–liver axis is dysregulated in patients with cirrhosis and correlates with impaired intestinal defence
https://doi.org/10.1007/s12072-023-10636-4
Von Willebrand factor processing in patients with advanced chronic liver disease and its relation to portal hypertension and clinical outcome
https://doi.org/10.1007/s12072-023-10577-y
Funding for this research was provided by:
Medical Scientific Fund of the Major of the City of Vienna (No. 21047)
Medical University of Vienna
Article History
Received: 5 May 2023
Accepted: 27 July 2023
First Online: 21 August 2023
Declarations
:
: BeSi has received travel support from AbbVie and Gilead. IFV is a former full-time employee at Nordic Bioscience. BeSc received travel support from Abbvie and Gilead. DB has received travel support from AbbVie and Gilead, as well as speaker fees from AbbVie. PS received speaking honoraria from Bristol-Myers Squibb and Boehringer-Ingelheim, consulting fees from PharmaIN, and travel support from Falk and Phenex Pharmaceuticals. MP served as a speaker and/or consultant and/or advisory board member for AstraZeneca Bayer, Bristol-Myers Squibb, Ipsen, Eisai, Lilly, MSD, and Roche, and received travel support from Bayer, Bristol-Myers Squibb, and Roche. MT served as a speaker and/or consultant and/or advisory board member for Albireo, BiomX, Falk, Boehringer Ingelheim, Bristol-Myers SquibbGenfit, Gilead, Intercept, Janssen, MSD, Novartis, Phenex, Pliant, Regulus, and Shire and received travel support from AbbVie, Falk, Gilead, and Intercept as well as grants/research support from Albireo, Alnylam, Cymabay, Falk, Gilead, Intercept, MSD, Takeda, and UltraGenyx. He is also co-inventor of patents on the medical use of 24-norursodeoxycholic acid. MK is a full-time employee at Nordic Bioscience and among the original inventors and patent holders of the Nordic Bioscience biomarkers. TR served as a speaker and/or consultant and/or advisory board member speaking honoraria from AbbVie, Bayer, Boehringer-Ingelheim, Gilead, Intercept, MSD, Roche, Siemens, and W. L. Gore & Associates and received travel support from AbbVie, Boehringer-Ingelheim, Gilead, and Roche as well as grants/research support from AbbVie, Boehringer-Ingelheim, Gilead, Intercept, MSD, Myr Pharmaceuticals, Philips Healthcare, Pliant, Siemens, and W. L. Gore & Associates. MM served as a speaker and/or consultant and/or advisory board member for AbbVie, Gilead, Collective Acumen, Takeda, and W. L. Gore & Associates and received travel support from AbbVie and Gilead. DJL is a full-time employee at Nordic Bioscience and among the original inventors and patent holders of the Nordic Bioscience biomarkers. TL, RP, RM, PQ and AFS declare no conflict of interest.